Home › Trials › NCT06764693

Assessing long-term use of Risankizumab for Psoriatic Arthritis

Prospective Multi-country, Real-world, Multi-arm Study of Treatment PErsistence With RISankizumab in Psoriatic Arthritis (PERIS)

Observational AbbVie · NCT06764693

This study is testing how well Risankizumab works over a long time for adults with psoriatic arthritis who haven't had enough relief from other treatments.

Quick facts

Study typeObservational
Enrollment1200 (estimated)
Ages18 Years to 75 Years
SexAll
SponsorAbbVie Industry-sponsored
Drugs / interventionsrisankizumab
Locations132 sites (Quilmes, Buenos Aires and 131 other locations)
Trial IDNCT06764693 on ClinicalTrials.gov

What this trial studies

This study evaluates the long-term effectiveness and persistence of treatment with Risankizumab in adults diagnosed with psoriatic arthritis, compared to other advanced therapeutic options. It will involve approximately 900 to 1200 participants across 15 countries, focusing on those who have had an inadequate response to at least one disease-modifying antirheumatic drug. The study aims to gather real-world data on the management of psoriatic arthritis in clinical practice.

Who should consider this trial

Good fit: Ideal candidates are adults with a clinical diagnosis of psoriatic arthritis who have had symptoms for at least six months and have shown inadequate response to at least one DMARD.

Not a fit: Patients who have demonstrated an inadequate response to three or more biologic DMARDs or targeted synthetic DMARDs may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide valuable insights into the long-term effectiveness of Risankizumab, potentially improving treatment strategies for patients with psoriatic arthritis.

How similar studies have performed: Other studies have shown success with similar approaches in evaluating treatment persistence and effectiveness in psoriatic arthritis, indicating that this methodology is supported by prior research.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Participant with a clinical diagnosis of psoriatic arthritis (PsA) with symptom onset at least 6 months prior to the Screening visit and fulfillment of ClASsification for Psoriatic ARthritis (CASPAR) at Baseline visit to confirm that the participant has active disease.
* Participant must have demonstrated an inadequate response to at least 1 Disease-modifying antirheumatic drug (DMARD) (with max 50% Biologic DMARD-Inadequate Response); alternatively, participant must have demonstrated an intolerance to or contraindication for csDMARDs as determined by the investigator.

Exclusion Criteria:

\- Participants demonstrated an inadequate response to three or more bDMARDs/targeted synthetic DMARDs (tsDMARDs).

Where this trial is running

Quilmes, Buenos Aires and 131 other locations

+82 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Psoriatic ArthritisRisankizumab, Skyrizi
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.